These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 19442565)

  • 21. Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma.
    Moskovitz JM; Ferris RL
    J Dent Res; 2018 Jun; 97(6):622-626. PubMed ID: 29489423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cells and HNSCC: a potential treatment option? (Review).
    Dunn G; Oliver KM; Loke D; Stafford ND; Greenman J
    Oncol Rep; 2005 Jan; 13(1):3-10. PubMed ID: 15583794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption.
    Rancoule C; Vallard A; Espenel S; Guy JB; Xia Y; El Meddeb Hamrouni A; Rodriguez-Lafrasse C; Chargari C; Deutsch E; Magné N
    Oral Oncol; 2016 Nov; 62():153-162. PubMed ID: 27623508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunobiology and immunotherapy of head and neck cancer.
    Whiteside TL
    Curr Oncol Rep; 2001 Jan; 3(1):46-55. PubMed ID: 11123869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy for head and neck squamous cell carcinoma.
    Li Q; Prince ME; Moyer JS
    Oral Oncol; 2015 Apr; 51(4):299-304. PubMed ID: 25624094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunotherapy of head and neck cancer. Current developments].
    Schuler PJ; Hoffmann TK; Gauler TC; Bergmann C; Brandau S; Lang S
    HNO; 2013 Jul; 61(7):559-72. PubMed ID: 23247754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
    Laban S; Doescher J; Schuler PJ; Bullinger L; Brunner C; Veit JA; Hoffmann TK
    HNO; 2015 Sep; 63(9):612-9. PubMed ID: 26319429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
    Voskens CJ; Sewell D; Hertzano R; DeSanto J; Rollins S; Lee M; Taylor R; Wolf J; Suntharalingam M; Gastman B; Papadimitriou JC; Lu C; Tan M; Morales R; Cullen K; Celis E; Mann D; Strome SE
    Head Neck; 2012 Dec; 34(12):1734-46. PubMed ID: 22287423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tailored immunotherapy for HPV positive head and neck squamous cell cancer.
    Gildener-Leapman N; Lee J; Ferris RL
    Oral Oncol; 2014 Sep; 50(9):780-4. PubMed ID: 24126224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
    Bauman JE; Cohen E; Ferris RL; Adelstein DJ; Brizel DM; Ridge JA; O'Sullivan B; Burtness BA; Butterfield LH; Carson WE; Disis ML; Fox BA; Gajewski TF; Gillison ML; Hodge JW; Le QT; Raben D; Strome SE; Lynn J; Malik S
    Cancer; 2017 Apr; 123(7):1259-1271. PubMed ID: 27906454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma.
    Moon JH; Chung MK; Son YI
    Laryngoscope; 2012 Nov; 122(11):2442-6. PubMed ID: 22926978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy in head and neck cancer: evidence and perspectives.
    Tosoni A; Franceschi E; Pasquini E; Lanese A; Donini E; Foschini MP; Dall'Olio D; Brandes AA
    Immunotherapy; 2017 Dec; 9(16):1351-1358. PubMed ID: 29185392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous-cell carcinomas of the head and neck.
    Sung MW; Yasumura S; Johnson JT; Van Dongen GA; Whiteside TL
    Int J Cancer; 1995 Jun; 61(6):864-72. PubMed ID: 7790123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma.
    Almokadem S
    Curr Mol Pharmacol; 2016; 9(3):226-230. PubMed ID: 26177644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
    Mayer A; Andratschke M; Pauli C; Graefe H; Kristina K; Wollenberg B
    Anticancer Res; 2005; 25(6B):4075-80. PubMed ID: 16309201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for Head and Neck Cancer.
    Sim F; Leidner R; Bell RB
    Oral Maxillofac Surg Clin North Am; 2019 Feb; 31(1):85-100. PubMed ID: 30449528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for head and neck cancer: advances and deficiencies.
    De Costa AM; Young MR
    Anticancer Drugs; 2011 Aug; 22(7):674-81. PubMed ID: 21037467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC.
    Weise JB; Maune S; Görögh T; Kabelitz D; Arnold N; Pfisterer J; Hilpert F; Heiser A
    Auris Nasus Larynx; 2004 Jun; 31(2):149-53. PubMed ID: 15121224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Checkpoint immunotherapy in head and neck cancers.
    Zolkind P; Uppaluri R
    Cancer Metastasis Rev; 2017 Sep; 36(3):475-489. PubMed ID: 28836124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].
    Hoffmann TK; Whiteside TL; Bier H
    HNO; 2005 Mar; 53(3):285-97; quiz 298. PubMed ID: 15759168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.